Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

Eileen O'Reilly
Published: Monday, Jan 08, 2018



Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.

According to O'Reilly, there is compelling science and biology behind using immunotherapy combinations in pancreatic cancer, since single-agent checkpoint inhibitors are insufficient.

In pancreatic cancer, the most promising combination is immunotherapy with a cytotoxic backbone, says O'Reilly. The disease needs to be under control for immunotherapy to work, which is why this combination has become a focus for this patient population.
 
SELECTED
LANGUAGE


Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.

According to O'Reilly, there is compelling science and biology behind using immunotherapy combinations in pancreatic cancer, since single-agent checkpoint inhibitors are insufficient.

In pancreatic cancer, the most promising combination is immunotherapy with a cytotoxic backbone, says O'Reilly. The disease needs to be under control for immunotherapy to work, which is why this combination has become a focus for this patient population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x